Clinical trials
Terminated Triple Negative Breast Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
154 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 2 |
| 2010 | 7 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 9 |
| 2016 | 12 |
| 2017 | 15 |
| 2018 | 15 |
| 2019 | 18 |
| 2020 | 20 |
| 2021 | 17 |
| 2022 | 13 |
| 2023 | 5 |
| 2024 | 8 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 154 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 7 |
| Pfizer | 7 |
| M.D. Anderson Cancer Center | 6 |
| Novartis Pharmaceuticals | 5 |
| Sun Yat-sen University | 4 |
| Genmab | 3 |
| University of Wisconsin, Madison | 3 |
| Washington University School of Medicine | 3 |
| AbbVie | 2 |
| Barbara Ann Karmanos Cancer Institute | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Triple Negative Breast Neoplasms | 154 |
| Breast Neoplasms | 57 |
| Carcinoma, Non-Small-Cell Lung | 43 |
| Ovarian Neoplasms | 26 |
| Squamous Cell Carcinoma of Head and Neck | 24 |
| Melanoma | 22 |
| Carcinoma, Renal Cell | 21 |
| Neoplasm Metastasis | 20 |
| Stomach Neoplasms | 14 |
| Colorectal Neoplasms | 13 |
Trials
Showing 26 to 50 of 154. Each trial links to its page on Pharma Observatory.
54 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.